Liposomal formulation of 5-fluorocytosine in suicide gene therapy with cytosine deaminase - for colorectal cancer

Cancer Letters

Volumn 262, Issue 2, 2008, Pages 164-172

  Chaszczewska Markowska, Monika ^a   Stebelska, Katarzyna ^b   Sikorski, Aleksander ^b   Madej, Janusz ^c   Opolski, Adam ^a   Ugorski, Maciej ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

^c WROCLAW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

Author keywords

E. coli cytosine deaminase; Gene directed enzyme prodrug therapy; Liposomes

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CHOLESTEROL; CYTOSINE DEAMINASE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; FLUCYTOSINE; LIPOSOME; PRODRUG; VIRUS VECTOR;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG FORMULATION; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE TRANSFER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SUICIDE GENE THERAPY;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; LIPOSOMES; MALE; MICE; MICE, INBRED C57BL; TRANSFECTION;

ANIMALIA; ESCHERICHIA COLI; MUS;

EID: 40649104944     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.12.006     Document Type: Article

References (30)

1. Chen M.-J., Chung-Faye G.A., Searle P.F., Young L.S., and Kerr D.J. Gene therapy for colorectal cancer. BioDrugs 15 (2001) 357-367
2. Chung-Faye G.A., Kerr D.J., Young L.S., and Searle P.F. Gene therapy strategies for colon cancer. Mol. Med. Today 6 (2000) 82-87
3. Xu G., and McLeod H.L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 7 (2001) 3314-3324
4. Huber B.E., Austin E.A., Richards C.A., Davis S.T., and Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91 (1994) 8302-8306
5. Mullen C.A., Coale M.M., Lowe R., and Blease R.M. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res. 54 (1994) 1503-1506
6. Lan K.-H., Kanai F., Shiratori Y., Ohashi M., Tanaka T., Okudaira T., Yoshida Y., Hamada H., and Omata M. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 57 (1997) 4279-4284
7. Ueda K., Iwahashi M., Nakamori M., Nakamura M., Matsuura I., Yamaue H., and Tanimura H. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the Cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 61 (2001) 6158-6162
8. Cao G., Kuriyama S., Gao J., Kikukawa M., Cui L., Nakatani T., Zhang X., Tsujinoue H., Pan X., Fukui H., and Qi Z. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther. 6 (1999) 83-90
9. Gabizon A. Emerging role of liposomal drug carrier systems in cancer chemotherapy. Liposome Res. 13 (2003) 17-20
10. Harrington K.J., Syrigos K.N., and Vile R.G. Liposomally targeted cytotoxic drugs for the treatment of cancer. J. Pharm. Pharmacol. 54 (2002) 1573-1600
11. Allen T.M., and Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta 1068 (1991) 133-141
12. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., and Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95 (2001) 4607-4612
13. Yuan F., Dellian M., Fukumura D., Leuning M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
14. Bendas G., Rothe U., Scherphof G.L., and Kamps J.A. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim. Biophys. Acta 1609 (2003) 63-70
15. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
16. Safra T., Muggia F., Jeffers S., Tsao-Wei D.D., Groshen S., Lyass O., Henderson R., Berry G., and Gabizon A. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/ml. Ann. Oncol. 11 (2000) 1029-1033
17. Cagnoni P.J. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Antimicrob. Chemother. 49 (2002) 81-86
18. Pajtasz-Piasecka E., Szyda A., Rossowska J., Krawczenko A., Indrowa M., Grabarczyk P., Wysocki P., Mackiewicz A., and Duś D. Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol. (Praha) 50 (2004) 7-14
19. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 (1990) 1107-1112
20. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. (1999) 691-743
21. Haviv Y.S., and Blackwell J. Transcriptional regulation in cancer gene therapy. Isr. Med. Assoc. J. 3 (2001) 517-522
22. Kijima T., Osaki T., Nishino K., Kumagai T., Funakoshi T., Goto H., Tachibana I., Tanio Y., and Kishimoto T. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res. 59 (1999) 4906-4911
23. Vermes A., Guchelaar H.J., and Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46 (2000) 171-179
24. Szebeni J., Alving C.R., Rosivall L., Bünger R., Baranyi L., Bedöcs P., Tóth M., and Barenholz Y. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 17 (2007) 107-117
25. McLintock L.A., Cook G., Holyoake T.L., Jones B.L., Kinsey S.E., and Jackson G.H. High loading dose AmBisome is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica 92 (2007) 572-573
26. Garg M., Dutta T., and Jain N.K. Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm. 67 (2007) 76-85
27. R. Suzuki, T. Takizawa, Y. Kuwata, M. Mutoh, N. Ishiguro, N. Utoguchi, A. Shinohara, M. Eriguchi, H. Yanagie, K. Maruyama, Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome, Int. J. Pharm., doi:10.1016/j.ijpharm.2007.06.010.
28. Temming K., Schiffelers R.M., Molema G., and Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 8 (2005) 381-402
29. Leunig M., Yuan F., Menger M.D., Boucher Y., and Goetz A.E. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res. 52 (1992) 6553-6560
30. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., and McDonald D.M. Openings between defective endothelial cells tumor vessel leakiness. Am. J. Pathol. 156 (2000) 1363-1380